Experimental Treatment for Macular Telangiectasia Type 2 Earns Fast Track Designation

According to a story from prnewswire.com, the biopharmaceutical company Neurotech Pharmaceuticals recently announced that the company had earned Fast Track designation from the US Food and Drug Administration (FDA). This…

Continue Reading Experimental Treatment for Macular Telangiectasia Type 2 Earns Fast Track Designation